2021 CMSC Annual Meeting

Tag: MA and Joshua D Katz

Poster-Disease-modifying Therapy

Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)

Background: The efficacy and safety of cladribine tablets 3.5 mg/kg (cumulative dose over 2 years) have been shown in patients …...

Read More